Elicio Therapeutics, Inc. - ELTX Profit before interest, taxes and amortization

Brandmark of Elicio Therapeutics, Inc. (ELTX)

Elicio Therapeutics (ELTX) does not pay dividends, focusing instead on its AMP platform for immune activation in lymph nodes. The company's estimated EBITDA serves as a confidence indicator, and this metric has now reached the level of 0.00. Transparent management is leading the business through its pre-revenue stage, while positive vaccine tests against solid tumors sustain market optimism despite intensive R&D expenditures.

ELTX Elicio Therapeutics Inc. Profit before payment of interest, taxes and amortization (11/23/2025 - 11/14/2026)

Summary analytical data breakdowns for Elicio Therapeutics, Inc. (ELTX)

- stock price and consensus target price:
Price Chart Elicio Therapeutics, Inc|ELTX - Consensus Target
- issuer market value details:
Market Value Elicio Therapeutics|ELTX - Total Company Value
- book capitalization data:
Accounting Value per Share Elicio Therapeutics|ELTX - Company Book Value|Market Capitalization to Net Assets elicio.com|ELTX - Company Total Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Elicio Therapeutics|ELTX - Long-Term Debt to Equity|Current Liabilities to Capital Elicio Therapeutics Inc.|ELTX - Company Debts|Debt to Book Value Ratio Elicio Therapeutics|ELTX - Company Long-Term Debt|Short-Term Debt Elicio Therapeutics|Immediate Liquidity Ratio elicio.com
- earnings and multiples data:
ELTX - Net Profit|Expected Net Profit Elicio Therapeutics|ELTX - Price to Earnings Ratio|Market Cap to Projected Earnings elicio.com|ELTX - PEG Multiple|Company Value to EBITDA Elicio Therapeutics|ELTX - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Elicio Therapeutics|ELTX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months elicio.com|ELTX - Earnings growth in current year|Expected earnings per share growth for next year Elicio Therapeutics
- sales and revenue data:
ELTX - Revenue and Sales Volume|Company Future Sales Elicio Therapeutics, Inc|ELTX - Price-to-Revenue Ratio|Market Cap to Future Revenue Ratio Elicio Therapeutics
Analysis of all company metrics:Elicio Therapeutics, Inc - ELTX
Brand item of Elicio Therapeutics

Elicio Therapeutics (ELTX) cancer vaccine development is independent of macroeconomic cycles, as business success is determined by the biological efficacy of the drugs during clinical trials. An analysis of operating income before taxes and depreciation allows for an assessment of the real cash flow from core operations without depreciation distortions, helping investors determine the sustainability of R&D funding amid inflationary pressure on costs.

Competitors of Elicio Therapeutics (ELTX)

Corvus Corp - Profit before payment of interest, taxes and amortization|PRLD: Operating profit before deduction of amortization